Marc Gittleman

Phase 1/2 dose‐escalation study of a GM‐CSF‐secreting, allogeneic, cellular immunotherapy for metastatic hormone‐refractory prostate cancer

Celestia S. Higano, John M. Corman, David C. Smith et al. · Cancer · 2008 · 212 citations · Full text

Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia

Claus G. Roehrborn, Leonard S. Marks, Tom Fenter et al. · Urology · 2004 · 144 citations

Urology, Erectile Dysfunction, Benign Prostatic Hyperplasia +4

A Phase 3, Multicenter, Open Label, Randomized Study Of Abarelix Versus Leuprolide Plus Daily Antiandrogen In Men With Prostate Cancer

The Abarelix Study Group, John Trachtenberg, Marc Gittleman et al. · The Journal of Urology · 2002 · 132 citations

A Phase 3, Multicenter, Open Label, Randomized Study Of Abarelix Versus Leuprolide Plus Daily Antiandrogen In Men With Prostate Cancer

John Trachtenberg, Marc Gittleman, Christopher P. Steidle et al. · The Journal of Urology · 2002 · 131 citations

Mg. Abarelix Depot, Hormonal Contraceptive, Urology +15

Intracavernous alprostadil alfadex is more efficacious, better tolerated, and preferred over intraurethral alprostadil plus optional ACTIS: a comparative, randomized, crossover, multicenter study

Ridwan Shabsigh, Harin Padma-Nathan, Marc Gittleman et al. · Urology · 2000 · 124 citations

Intracavernous Alprostadil Alfadex, Optional Actis, Orthopaedics +5